A Study of NT-175 in Adult Subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Trial Identifier: NT-175-201
Sponsor: AstraZeneca
Collaborator:
AstraZeneca
Start Date: July 2023
Primary Completion Date: September 2028
Study Completion Date: August 2039
Condition: Breast Cancer; Colorectal Cancer; Cancer - Other; Lung Cancer; Ovarian Cancer; Pancreatic Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AZ Gilbert, AZ, US, 85234
US, CA Duarte, CA, US, 91010
US, CA Newport Beach, CA, US, 92663
US, CA Santa Monica, CA, US, 90404
US, FL Jacksonville, FL, US, 32224
US, FL Miami, FL, US, 33136
US, FL Tampa, FL, US, 33612
US, MA Boston, MA, US, 02115
US, NC Charlotte, NC, US, 28204
US, NC Winston Salem, NC, US, 27103
US, NJ New Brunswick, NJ, US, 08901
US, NY New York, NY, US, 10065
US, OR Portland, OR, US, 97213
US, PA Pittsburgh, PA, US, 15232
US, TN Nashville, TN, US, 37203
US, TX Houston, TX, US, 77030
US, TX Round Rock, TX, US, 78665
US, WI Milwaukee, WI, US, 53226